SCHEMBL1010618

SCHEMBL1010618

COc1cc(CC(=O)O)ccc1C

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 6/20 0.70
TSHR P16473 2/20 0.70
NFKB1 P19838 2/20 0.70
TDP1 Q9NUW8 2/20 0.70
ALDH1A1 P00352 1/20 0.70
SLC22A12 Q96S37 1/20 0.61
CA5A P35218 1/20 0.60
PTGS1 P23219 1/20 0.56
AKR1C3 P42330 1/20 0.56
AKR1C2 P52895 1/20 0.56
NPSR1 Q6W5P4 1/20 0.54
SELL P14151 1/20 0.50
SELP P16109 1/20 0.50
HSD17B10 Q99714 2/20 0.47
LDHA P00338 1/20 0.47
LMNA P02545 3/20 0.47
MAPT P10636 2/20 0.47
HPGD P15428 2/20 0.47
KDM4E B2RXH2 1/20 0.47
RGS12 O14924 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30094539 0.86 GAA (0.70) GAATSHRNFKB1TDP1ALDH1A1
SCHEMBL17065172 0.86 GAA (0.51) GAATSHRNFKB1TDP1ALDH1A1
SCHEMBL969758 0.86 GAA (0.70) GAATSHRNFKB1TDP1ALDH1A1
SCHEMBL153055 0.85 GAA (0.74) GAATSHRNFKB1TDP1ALDH1A1
SCHEMBL30049382 0.85 GAA (0.74) GAATSHRNFKB1TDP1ALDH1A1
SCHEMBL13813952 0.84 ALDH1A1 (0.53) GAATSHRNFKB1TDP1ALDH1A1
SCHEMBL16480608 0.84 EPHX2 (0.52) GAATSHRNFKB1TDP1ALDH1A1
Hydrochloric Acid SCHEMBL2530820 0.84 GAA (0.72) GAATSHRNFKB1TDP1ALDH1A1
SCHEMBL27952523 0.84 GAA (0.72) GAATSHRNFKB1TDP1ALDH1A1
SCHEMBL334173 0.83 SLC22A12 (0.63) GAATSHRNFKB1TDP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4734977-A2 NOVEL TRPV1 AGONISTS AND USES THEREOF Neucures, Inc. (US) 2026-05-06 EP disclosed
EP-4562011-A1 IMMUNOMODULATOR PURINE-DERIVED COMPOUNDS, CONJUGATES THEREOF, AND METHODS OF USE THEREOF Zymeworks BC Inc. (CA) 2025-06-04 EP disclosed
US-20250170266-A1 IMMUNOMODULATOR PURINE-DERIVED COMPOUNDS, CONJUGATES THEREOF, AND METHODS OF USE THEREOF ZYMEWORKS BC INC. (CA) 2025-05-29 US disclosed
WO-2025006675-A9 NOVEL TRPV1 AGONISTS AND USES THEREOF NEUCURES, INC. (US) 2025-03-13 WO disclosed
WO-2025006675-A2 NOVEL TRPV1 AGONISTS AND USES THEREOF NEUCURES, INC. (US) 2025-01-02 WO disclosed
WO-2024020684-A1 IMMUNOMODULATOR PURINE-DERIVED COMPOUNDS, CONJUGATES THEREOF, AND METHODS OF USE THEREOF ZYMEWORKS BC INC. (CA) 2024-02-01 WO disclosed
CN-113234079-B Nucleoside analogs as PRMT5 inhibitors 上海湃隆生物科技有限公司 2022-02-01 CN disclosed
CN-113234079-A Nucleoside analogs as PRMT5 inhibitors 上海湃隆生物科技有限公司 2021-08-10 CN disclosed
WO-2019244047-A1 N-SUBSTITUTED TETRAHYDROTHIENOPYRIDINE DERIVATIVES AND USES THEREOF NOVARTIS AG (CH) 2019-12-26 WO disclosed
EP-3517109-A1 COMPOUNDS AND METHOD FOR REDUCING URIC ACID Wellstat Therapeutics Corporation (US) 2019-07-31 EP disclosed
US-7465811-B2 Indoline compounds LABORATOIRES FOURNIER S.A. (FR) 2008-12-16 US disclosed
WO-2008079382-A1 SPHINGOSINE-1 -PHOSPHATE RECEPTOR AGONIST AND ANTAGONIST COMPOUNDS ABBOTT LABORATORIES (US) 2008-07-03 WO disclosed
US-20080119465-A1 Novel Indoline Compounds LABORATORIES FOURNIER S.A. (FR) 2008-05-22 US disclosed
US-20080119465-A1 Novel Indoline Compounds LABORATORIES FOURNIER S.A. (FR) 2008-05-22 US disclosed
WO-2007149728-A2 ARYL AND HETEROARYL TETRAHYDROBENZAZEPINE DERIVATIVES AND THEIR USE FOR TREATING GLAUCOMA ALCON RESEARCH, LTD. (US) 2007-12-27 WO disclosed
WO-2007149728-A2 ARYL AND HETEROARYL TETRAHYDROBENZAZEPINE DERIVATIVES AND THEIR USE FOR TREATING GLAUCOMA ALCON RESEARCH, LTD. (US) 2007-12-27 WO disclosed
US-20070293475-A1 ARYL AND HETEROARYL TETRAHYDROBENZAZEPINE DERIVATIVES AND THEIR USE FOR TREATING GLAUCOMA ALCON MANUFACTURING LTD. (US) 2007-12-20 US disclosed
US-20070293475-A1 ARYL AND HETEROARYL TETRAHYDROBENZAZEPINE DERIVATIVES AND THEIR USE FOR TREATING GLAUCOMA ALCON MANUFACTURING LTD. (US) 2007-12-20 US disclosed
US-20070293475-A1 ARYL AND HETEROARYL TETRAHYDROBENZAZEPINE DERIVATIVES AND THEIR USE FOR TREATING GLAUCOMA ALCON MANUFACTURING LTD. (US) 2007-12-20 US disclosed
WO-2007000550-A2 NOVEL INDOLINE COMPOUNDS LABORATOIRES FOURNIER S.A. (FR) 2007-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119465-A1 Novel Indoline Compounds GPR119, INSR, IRS1 GAA 1612/4885TSHR 681/4885NFKB1 1021/4885
US-20070293475-A1 ARYL AND HETEROARYL TETRAHYDROBENZAZEPINE DERIVATIVES AND THEIR USE FOR TREATING GLAUCOMA HTR2B, HTR2A, HTR3B GAA 1712/4885TSHR 815/4885NFKB1 3417/4885
US-20250170266-A1 IMMUNOMODULATOR PURINE-DERIVED COMPOUNDS, CONJUGATES THEREOF, AND METHODS OF USE THEREOF PAICS, ENTPD5, PNP GAA 981/4885TSHR 3200/4885NFKB1 943/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.